|Videos|July 5, 2023
Key Takeaways from Health Care Systems on the Role of Bispecifics in MM
The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
2
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
3
Neoadjuvant BOT + BAL Yields Pathologic Responses in pMMR/dMMR Colon Cancer
4
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
5